Man wins $50,000 twice in one month from the same lottery game
July 17 (UPI) -- An Arkansas man scored a $50,000 prize from a scratch-off lottery ticket less than a month after winning the same amount from the same game.
The Arkansas Scholarship Lottery said the Pulaski County player, identified as Travis S., bought a $20 $50,000 Frenzy ticket from the Kum & Go store on Chenal Parkway in Little Rock and scratched off a $50,000 prize.
His surprise was compounded by the fact that he had already won the same amount from the same game earlier in July.
"There's no way I won again on this ticket!" Travis recalled thinking.
He credited his second win to doing a good deed just before buying his ticket. He said he had given $100 to a stranger in distress just before making his purchase, and his good karma paid off.
Travis said his winnings will go toward purchasing a car and buying his stepdaughter some new volleyball shoes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
3 minutes ago
- UPI
UnitedHealth Group says it's cooperating with DOJ Medicare probe
Attorney General Pam Bondi speaks during a press briefing in June. UnitedHealth said its facing an investigation from the Department of Justice about its Medicare billing practices. Photo by Yuri Gripas/UPI | License Photo July 24 (UPI) -- UnitedHealth Group said Thursday it is facing Department of Justice investigations over its Medicare billing practices. UnitedHealth Group said in a statement on its website that it reached out to the DOJ after seeing media reports about investigations into its Medicare program. "(UnitedHealth) has now begun complying with formal criminal and civil requests from the Department. The Company has full confidence in its practices and is committed to working cooperatively with the Department throughout this process," the statement said. The insurer said it's launching its own investigation. "To provide our stakeholders transparency and confidence (UnitedHealth) ... has proactively launched its own initiative to conduct third party reviews of policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services." The company told CNBC that it expects to complete that review near the end of the third quarter. The Wall Street Journal reported in May that the Justice Department is conducting a criminal investigation into UHC for Medicare fraud. The company said it stands "by the integrity of our Medicare Advantage program." The Journal reported in July that the DOJ interviewed doctors about UnitedHealth's practices and asked if they felt pressured to submit claims for certain conditions that bolstered payments from the Medicare Advantage program. "(UnitedHealth) is committed to maintaining the integrity of its business practices and serving as reliable stewards of American tax dollars," UnitedHealth said. This is just the latest setback for the country's largest health insurer. Shares are down more than 42%, its CEO Andrew Witty left the company in May, it suffered a ransomware attack in early 2024, and then CEO Brian Thompson was killed in December 2024 by alleged shooter Luigi Mangione, which sparked significant public outrage against the company.
UPI
an hour ago
- UPI
South Korea's Samsung Biologics, Celltrion log stellar performances
1 of 2 | South Korean biopharmaceutical contract manufacturer Samsung Biologics posted a stellar performance in the first half of this year. Photo courtesy of Samsung Biologics SEOUL, July 24 (UPI) -- The South Korean economy struggles as the country's gross domestic product growth rate is feared to more than halve to less than 1% this year, compared to 2% for 2024. However, its defense and shipbuilding industries are faring well. Also among the high achievers are biopharmaceutical contract manufacturers, including Samsung Biologics and Celltrion. Samsung Biologics, one of the world's largest contract development and manufacturing organizations, or CDMOs, announced Wednesday that it posted record-high $1.88 billion in sales during the first six months of 2025, up 21.3% from a year earlier. Its operating profit amounted to $700 million, up 46.75%. The company also said that it has signed contracts worth $2.4 billion in the first half of the year, which is more than 60% of its total annual order volume for 2024. "As global demand for CDMO services continues to rise, we are rapidly expanding our production capacity," Samsung Biologics said in a statement. "Backed by our world-class CDMO capabilities, we plan to intensify our efforts to win more orders, particularly targeting the world's top 40 pharmaceutical companies." Samsung's local rival, Celltrion, is likewise seeing impressive results. The outfit announced Tuesday that its first-half turnover stood at $1.31 billion, up 11.9% year-on-year. Its operating income more than tripled to $285 million. The company's sales for this year are expected to top $3 billion for the first time, and its bottom line is projected to near the $1 billion mark. Observers have positive outlooks for the two powerhouses. "Samsung Biologics is beefing up its global competitiveness through the second campus, which includes plants five to eight," KB Securities researcher Kim Hye-min said in a market report. "The company is also expanding its capabilities beyond traditional monoclonal antibody-focused CDMO services to next-generation modalities and pre-filled syringes," she noted. Prefilled syringe manufacturing means that Samsung Biologics rolls out drugs in ready-to-inject formats. Global pharmaceutical clients tend to request this for chronic diseases or biologic treatments. Regarding Celltrion, Heungkuk Securities analyst Lee Ji-won said in a recent report that this year would be a pivotal point for the company's profit growth momentum. "Celltrion is predicted to demonstrate a significant year-on-year increase in profits, driven by the solid performance of newly launched high-margin biosimilars," Lee said. Experts said the CDMO businessm which is based on outsourced manufacturing, is an area in which Korean companies have advantages. "Although the Korean economy languishes due to various reasons this year, the biopharmaceutical outsourcing business is likely to rack up stellar performances for the time being. Samsung Biologics and Celltrion will spearhead the trend," Seoul-based business tracker Leaders Index CEO Park Ju-gun told UPI. "Samsung Biologics has already become an established player in the market, favored by global biopharmaceutical giants thanks to its cost competitiveness and quick delivery. Celltrion is also trying hard to become a big name in the market," he said. Economic analyst Kim Joon-Kyung, formerly vice chairman at Deloitte Consulting Korea, agreed. "First of all, the CDMO industry is promising. And from the perspective of Samsung, the business shares many characteristics with semiconductor production. Hence, the group had a good reason to tap into the CDMO sector," Kim said in a phone interview. "Celltrion did not have such advantages. But the company secured technological edges early on, which is quite an achievement. That's why Celltrion is showing solid performances now," he said. Samsung Electronics, the mother company of Samsung Biologics, is the world's largest maker of memory chips. According to U.S. market intelligence firm BCC Research, the global CDMO market is expected to expand to $191.6 billion by 2029 from $136.6 billion last year based on mounting demand for outsourced drug development and manufacturing. Other biopharmaceutical companies in Korea also are striving to tap into the lucrative CDMO business, including SK Bioscience and Lotte Biologics. Toward that end, SK Bioscience acquired a controlling stake in IDT Biologika of Germany, which is one of the top 10 global vaccine CDMOs, late last year. Lotte Biologics has launched operations of its antibody-drug conjugate facility at its Syracuse Bio Campus in the United States. The company also is preparing its first plant located just west of Seoul, aiming to begin commercial production in 2027.
UPI
an hour ago
- UPI
U.K. and India sign 'Comprehensive Economic and Trade Agreement'
British Prime Minister Keir Starmer and India's Prime Minister Narendra Modi met on Thursday to sign a trade agreement between the two nations. Pool Photo by Chris J. Ratcliffe/EPA July 24 (UPI) -- Britain and India agreed to a free trade agreement between their two nations Thursday. "A new chapter begins today in the India-U.K. economic partnership," said Indian Prime Minister Narendra Modi on his social media platform Thursday. "The signing of the Comprehensive Economic and Trade Agreement reflects our shared commitment to enhancing trade, driving inclusive growth and creating opportunities for farmers, women, youth, [Micro, Small, and Medium Enterprises] and professionals." The deal is expected to inject over $6.5 billion into the British economy and create more than $8 billion by way of investments from companies based in both countries. "Our landmark trade deal with India is a major win for Britain," British Prime Minister Keir Starmer posted to X Thursday. "This is about putting more money in the pockets of hardworking Brits and helping families with the cost of living." Modi and Starmer met and held a press conference on Thursday at Starmer's country house in Buckinghamshire County. Job growth in sectors such as technology, aerospace and manufacturing is expected, as noted in a press release from the U.K. Thursday. "Thanks to the deal, British workers will enjoy a collective uplift in wages of [nearly $3 billion] each year and could also see cheaper prices and more choice on clothes, shoes, and food products," the statement said. Scottish Labor Party MP Ian Murray praised the deal online Thursday. "The India Trade Deal is great news for Scottish jobs and business," Murray posted to X. "The landmark agreement will deliver [an over $257 million] boost for the Scottish economy as part of the Plan for Change." The U.K. Plan for Change are the current goals sought to achieve by the current British government. The agreement is also anticipated to make imported goods cheaper for Indian consumers, according to a press release from the Indian government Thursday, which would include luxury cars, gin, Scotch whisky, cosmetics and medical devices. "Within the next two years, India's leather industry is projected to increase its market share in the U.K. by 5%," the release said. Bharti Enterprises conglomerate Founder and Chairman Sunil Bharti Mittal accompanied Modi as a delegate to meet with Starmer in England. "This agreement establishes a modern, forward-looking partnership that will stimulate innovation, ease market access, and foster investment," said Mittal. "Businesses in both India and the U.K. stand to benefit as this lays the foundation for expanding bilateral cooperation across key growth sectors." Tariffs between the U.K. and India will also lessen, as Britain will reduce levies on 99% of Indian exports, while India will decrease tariffs on 90% of British goods. The trade deal will "add momentum to the 'Make in India' led growth and export promotion," said Modi Thursday. "The future indeed holds the promise of greater prosperity and deeper ties between our nations."
